Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
135 participants
INTERVENTIONAL
2018-12-01
2020-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
NCT01485978
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
NCT00921570
Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
NCT04531397
Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy
NCT00738660
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
NCT01500590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ramipril
Ramipril, 2.5 mg daily, administered orally for 16 weeks
Ramipril
angiotensin-converting enzyme inhibitor
Placebo
Placebo, matched for the interventional drug, administered orally, daily for 16 weeks
placebo
same odor, color and size as the drug but without the active ingredient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ramipril
angiotensin-converting enzyme inhibitor
placebo
same odor, color and size as the drug but without the active ingredient
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have been on regular HD for 6 months or longer
* Hypertension at enrollment
Exclusion Criteria
* Acute infection within 1 month prior to the study
* Advanced liver disease
* Gastrointestinal dysfunction requiring parental nutrition or active malignancy
* Use of medications such as immunosuppressive drugs within 1 month prior to the study
* Use of anti-inflammatory medications
* Use of vitamin E at a dose higher than 60 IU per day or vitamin C higher than 500 mg per day
* History of myocardial infarction or cerebrovascular event within 3 months prior to the study
* History of ACE inhibitor-associated angioedema
* Inability to discontinue ACE inhibitors or ARBs
8 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Areej Mohamed Ateya
Assisstant lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ain Sh University
Role: PRINCIPAL_INVESTIGATOR
university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University Hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ateya AM, El Hakim I, Shahin SM, El Borolossy R, Kreutz R, Sabri NA. Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial. Hypertension. 2022 Aug;79(8):1856-1865. doi: 10.1161/HYPERTENSIONAHA.122.19312. Epub 2022 Jun 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHCL 65
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.